DJIA 16,115.21 -259.55 -1.59%
NASDAQ 4,687.72 -45.78 -0.97%
S&P 500 1,925.33 -25.80 -1.32%
market minute promo

Geron Corp (NASDAQ: GERN)

3.35 -0.10 (-2.90%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

GERN $3.35 -2.90%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $3.38
Previous Close $3.45
Daily Range $3.31 - $3.47
52-Week Range $1.76 - $4.67
Market Cap $529.8M
P/E Ratio -14.38
Dividend (Yield) $0.00 (0.0%)
Volume 1,447,476
Average Daily Volume 2,745,943
Current FY EPS -$0.07




Drug Makers

Geron Corp (GERN) Description

A biopharmaceutical company which is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS. Website:

News & Commentary

Here's Why Geron Corporation's Stock Is Ripping Higher Today

Geron Corp.'s stock jumped on the announcement that the New England Journal of Medicine published two papers today highlighting the unprecedented disease-modifying ability of its telomerase inhibitor imetelstat in two blood-based disorders.

Geron (GERN) Showing Signs Of Perilous Reversal Today

Health Care Sector Update for 09/03/2015: GERN,LCI,KERX

Morning Market Gainers

US Stock Futures Extend Gains as Jobless Claims Rise More Than Expected

Benzinga's Top #PreMarket Gainers

SA Biotech Panel Discussion: Geron And Incyte, Imetelstat And Jakafi

Could Geron Corporation Be the Next Big Biotech Winner?

Lets dig in to see if this small-cap stock could be the next home-run biotech investment.

Premarket Biotech Digest: Don't Panic Sell, Gilead Undervalued, Roche Acquiring GeneWEAVE

Geron Q2 Loss Narrower-than-Expected, Imetelstat in Focus - Analyst Blog

See More GERN News...

GERN's Top Competitors

GERN $3.35 (-2.90%)
Current stock: GERN
AMGN $147.54 (-1.13%)
Current stock: AMGN
GILD $102.60 (0.68%)
Current stock: GILD
BIIB $299.30 (-0.77%)
Current stock: BIIB